Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures.

Pae CU, Bodkin JA, Portland KB, Thase ME, Patkar AA.

J Clin Psychiatry. 2012 May;73(5):661-8. doi: 10.4088/JCP.12m07648.

PMID:
22697192
3.

The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.

Robinson DS, Amsterdam JD.

J Affect Disord. 2008 Jan;105(1-3):15-23. Epub 2007 Jun 13. Review.

PMID:
17568687
4.

Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.

Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS.

J Clin Psychiatry. 2006 Sep;67(9):1354-61.

PMID:
17017821
5.

Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.

Azzaro AJ, Vandenberg CM, Blob LF, Kemper EM, Sharoky M, Oren DA, Campbell BJ.

J Clin Pharmacol. 2006 Aug;46(8):933-44. Erratum in: J Clin Pharmacol. 2006 Oct;46(10):1225-6. Dosage error in article text.

PMID:
16855078
6.

Transdermal selegiline.

Patkar AA, Pae CU, Zarzar M.

Drugs Today (Barc). 2007 Jun;43(6):361-77. Review.

PMID:
17612708
8.

Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.

Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM.

J Am Acad Dermatol. 2005 Sep;53(3):407-15.

PMID:
16112345
9.

Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour.

Blob LF, Sharoky M, Campbell BJ, Kemper EM, Gilmor MG, VanDenberg CM, Azzaro AJ.

CNS Spectr. 2007 Jan;12(1):25-34.

PMID:
17192761
10.

Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.

Barrett JS, Hochadel TJ, Morales RJ, Rohatagi S, DeWitt KE, Watson SK, Darnow J, Azzaro AJ, DiSanto AR.

J Clin Pharmacol. 1997 Mar;37(3):238-47.

PMID:
9089426
11.

Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.

Clayton AH, Campbell BJ, Favit A, Yang Y, Moonsammy G, Piontek CM, Amsterdam JD.

J Clin Psychiatry. 2007 Dec;68(12):1860-6.

PMID:
18162016
12.

Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT.

MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. Erratum in: MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113.

13.

Psychopharmacology column: why choose selegiline transdermal system for refractory depression?

Tobin M.

Issues Ment Health Nurs. 2007 Feb;28(2):223-8. No abstract available.

PMID:
17365170
14.

Transdermal selegiline: the new generation of monoamine oxidase inhibitors.

Patkar AA, Pae CU, Masand PS.

CNS Spectr. 2006 May;11(5):363-75. Review.

PMID:
16641841
15.

Selegiline transdermal system: current awareness and promise.

Pae CU, Lim HK, Han C, Neena A, Lee C, Patkar AA.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1153-63. Epub 2007 May 10. Review.

PMID:
17614182
16.

Why the transdermal delivery of selegiline (6 mg/24 hr) obviates the need for a dietary restriction on tyramine.

Preskorn SH.

J Psychiatr Pract. 2006 May;12(3):168-72. No abstract available.

PMID:
16732136
17.

Transdermal selegiline: a novel MAOI formulation for depression.

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2006 Jul;44(7):9-12. Review. No abstract available.

PMID:
17310829
18.
19.

Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.

Henney HR 3rd, Chez M.

Paediatr Drugs. 2009;11(6):397-406. doi: 10.2165/11316090-000000000-00000.

PMID:
19877725
20.

Attempts to attenuate the 'cheese effect'. Combined drug therapy in depressive illness.

Pare CM, Al Mousawi M, Sandler M, Glover V.

J Affect Disord. 1985 Sep;9(2):137-41.

PMID:
2932486
Items per page

Supplemental Content

Write to the Help Desk